Last reviewed · How we verify
NCT03963596: COAST_UAmCNV
Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia
NA trial testing Intravitreal injection in Pathologic Myopia in 122 participants. Completed in 31 December 2020.
1 July 2020
Quick facts
| Lead sponsor | The Filatov Institute of Eye Diseases and Tissue Therapy |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 122 |
| Start date | 27 March 2018 |
| Primary completion | 1 July 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 3 locations across Ukraine |
Drugs / interventions tested
- Intravitreal injection — full drug profile →
Conditions studied
- Pathologic Myopia — all drugs for Pathologic Myopia →
Sponsor
The Filatov Institute of Eye Diseases and Tissue Therapy
Who can join
Adults 18 to 80, any sex, with Pathologic Myopia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to pathologic myopia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03963596
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intravitreal injection
Trials testing the same drug.
- NCT04976244 — Brolucizumab for CNV Associated With Pathologic Myopia · NA · unknown
- NCT03660345 — PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME · Phase 3 · completed
- NCT03648814 — Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT · NA · recruiting
- NCT04245072 — Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis · NA · unknown
- NCT04119219 — Antiangiogenic Therapy of CNV Associated With Angioid Streaks · NA · unknown
Other recruiting trials for Pathologic Myopia
Currently open trials in the same condition.
- NCT07312214 — LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia · NA · recruiting
- NCT06322433 — Follow up of High Myopic Eyes · recruiting
Other The Filatov Institute of Eye Diseases and Tissue Therapy trials
Trials by the same sponsor.
- NCT06927544 — Intraocular Gas Tamponade for Treatment of Large Idiopathic Macular Holes · NA · enrolling by invitation
- NCT04976244 — Brolucizumab for CNV Associated With Pathologic Myopia · NA · unknown
- NCT07375901 — the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration · NA · completed
- NCT04292756 — Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment · NA · completed
- NCT04245072 — Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03963596 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Filatov Institute of Eye Diseases and Tissue Therapy
- Last refreshed: 25 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03963596.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing